These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 16276591)

  • 21. What's new and what's next.
    Fakuda D
    Posit Dir News; 1998 Jan; 10(1):25-9. PubMed ID: 11365053
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial.
    Geretti AM; Arribas JR; Lathouwers E; Foster GM; Yakoob R; Kinloch S; Hill A; van Delft Y; Moecklinghoff C
    HIV Clin Trials; 2013; 14(1):45-50. PubMed ID: 23372114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral drugs: new agents, new combinations line up against HIV.
    Phillips L
    Hosp Technol Ser; 1996 Jan; 15(1):1-3. PubMed ID: 10161344
    [No Abstract]   [Full Text] [Related]  

  • 24. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Zalcitabine (Hivid).
    Res Initiat Treat Action; 2000 Mar; 6(1):10-1. PubMed ID: 11708175
    [No Abstract]   [Full Text] [Related]  

  • 26. Drifting agenda for federal treatment research.
    Huff B
    GMHC Treat Issues; 2001 May; 15(5):1-4. PubMed ID: 11548299
    [No Abstract]   [Full Text] [Related]  

  • 27. Use of newer antiretroviral agents, darunavir and etravirine with or without raltegravir, in pregnancy: a report of two cases.
    Jaworsky D; Thompson C; Yudin MH; Bitnun A; Brophy J; Samson L; Antoniou T; Loutfy MR
    Antivir Ther; 2010; 15(4):677-80. PubMed ID: 20587860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selected highlights from the 5th Conference on Retroviruses and Opportunistic Infections.
    Bartnof HS
    BETA; 1998 Apr; ():49-56. PubMed ID: 11365269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme.
    Florence E; De Wit S; Castagna A; Ribera E; Hill A; Vanaken H; van Delft Y; Marks S
    Int J STD AIDS; 2010 Mar; 21(3):224-5. PubMed ID: 20071441
    [No Abstract]   [Full Text] [Related]  

  • 30. Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial.
    Guaraldi G; Zona S; Cossarizza A; Vernacotola L; Carli F; Lattanzi A; Nardini G; Orlando G; Garlassi E; Termini R; Garau M
    Int J STD AIDS; 2014 Mar; 25(3):207-12. PubMed ID: 24216034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body fat distribution in HIV-infected patients treated for 96 weeks with darunavir/ritonavir monotherapy versus darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors: the MONOI-ANRS136 substudy.
    Valantin MA; Kolta S; Flandre P; Algarte Genin M; Meynard JL; Ponscarme D; Slama L; Cuzin L; de Kerviler E; Inaoui R; Katlama C
    HIV Med; 2012 Sep; 13(8):505-15. PubMed ID: 22416798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
    Flynn P; Komar S; Blanche S; Giaquinto C; Noguera-Julian A; Welch S; Lathouwers E; Van de Casteele T; Kakuda TN; Opsomer M
    Pediatr Infect Dis J; 2014 Sep; 33(9):940-5. PubMed ID: 25361024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
    Furtado J; Madruga JV; Bicudo EL; da Eira M; Lopes MI; Netto EM; Santini-Oliveira M; Leite OH; Machado AA; Tupinambas U; de Andrade Neto JL; Lima MP; Pedro Rde J; Miranda AF; Lewi DS; Santos BR; Portsmouth S; Wajsbrot DB; Cassoli LM
    AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1203-10. PubMed ID: 23731330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of once-daily maraviroc plus ritonavir-boosted darunavir in pretreated HIV-infected patients in a real-life setting.
    Macías J; Recio E; Márquez M; García C; Jiménez P; Merino D; Muñoz L; Pasquau J; Ojeda G; Bancalero P; Chueca N; Pineda JA
    HIV Med; 2014 Aug; 15(7):417-24. PubMed ID: 24580801
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amprenavir study results released.
    AIDS Patient Care STDS; 1999 Dec; 13(12):754. PubMed ID: 10743545
    [No Abstract]   [Full Text] [Related]  

  • 36. Retrovirus conference report: three new agents to the rescue.
    Gilden D
    GMHC Treat Issues; 1999 Jan; 13(1):1-4. PubMed ID: 11366110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 96-Week MERIT ES analysis shows efficacy of Celsentri=Selzentry.
    AIDS Patient Care STDS; 2009 Aug; 23(8):679. PubMed ID: 19694034
    [No Abstract]   [Full Text] [Related]  

  • 38. Resistance profile of darunavir: combined 24-week results from the POWER trials.
    de Meyer S; Vangeneugden T; van Baelen B; de Paepe E; van Marck H; Picchio G; Lefebvre E; de Béthune MP
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):379-88. PubMed ID: 18327986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients.
    Delaugerre C; Mathez D; Peytavin G; Berthé H; Long K; Galperine T; de Truchis P
    AIDS; 2007 May; 21(9):1210-3. PubMed ID: 17502734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Different evidence of key amprenavir resistance mutations on the efficacy of darunavir.
    Di Biagio A; Rosso R; Bruzzone B; Cenderello G; Dentone C; Mularoni A; Ferrea G; Icardi G; Viscoli C
    AIDS; 2008 Jan; 22(3):437-8. PubMed ID: 18195574
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.